Biotech firm, Adicet Bio, to unveil their developments at the H.C. Wainwright's 27th Annual Global Financial Meeting.
Adicet Bio, Inc., a clinical stage biotechnology company focusing on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025.
The presentation by Adicet Bio, Inc. is scheduled for 4:30 p.m. ET on the said date. For those who cannot attend in person, an archived replay of the presentation will be available for 30 days following the event on the company's website at http://www.adicetbio.com.
The live audio webcast of Adicet Bio, Inc.'s presentation can also be accessed on their website. For more information about the company, please visit their website at https://www.adicetbio.com.
Chen Schor, who was previously the Chief Operating Officer (COO) of Adicet Bio, Inc., has been appointed as the President and Chief Executive Officer. The company is developing "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs).
Adicet Bio, Inc.'s contact information for investors and media is as follows:
- Anne Bowdidge ([email protected])
- Penelope Belnap ([email protected])
For those seeking further information, contact details can also be obtained from Precision AQ at 212-362-1200.
The news about Adicet Bio, Inc. was provided by Business Wire via QuoteMedia. The source for this news can be found at https://www.businesswire.com/news/home/20250902137372/en/.
Please note that this news is not an advertisement. It is intended to provide information about Adicet Bio, Inc.'s upcoming presentation at the H.C. Wainwright 27th Annual Global Investment Conference.
